| ATC code G: Genito-urinary system and sex hormones |
|---|
|
| ATCvet only |
|
| Other ATC codes |
ATC code G Genito-urinary system and sex hormones is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QG. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
|---|---|
| gastrointestinal tract / metabolism (A) | |
| blood and blood forming organs (B) | |
| cardiovascular system (C) | |
| skin (D) | |
| genitourinary system (G) | |
| endocrine system (H) | |
| infections and infestations (J, P, QI) | |
| malignant disease (L01–L02) | |
| immune disease (L03–L04) | |
| muscles, bones, and joints (M) | |
| brain and nervous system (N) |
|
| respiratory system (R) | |
| sensory organs (S) | |
| other ATC (V) | |
| Antibiotics | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Arsenic compounds | |||||||||
| Quinoline derivatives | |||||||||
| Organic acids | |||||||||
| Sulfonamides | |||||||||
| Antifungals |
| ||||||||
| Other | |||||||||
| Cervical ripening |
| ||||
|---|---|---|---|---|---|
| Contraction induction | |||||
| |||||
Birth control methods | |||||||
|---|---|---|---|---|---|---|---|
| Related topics | |||||||
| Long-acting reversible contraception (LARC) | |||||||
| Sterilization |
| ||||||
| Hormonal contraception |
| ||||||
| Barrier Methods | |||||||
| Emergency Contraception (Post-intercourse) |
| ||||||
| Spermicides | |||||||
| Behavioral |
| ||||||
| Experimental | |||||||
Tocolytics/labor repressants (G02CA) | |
|---|---|
| β2 adrenoreceptor agonists | |
| Oxytocin antagonists | |
| NSAIDs | |
| Calcium channel blockers | |
| Myosin inhibitors | |
| Prolactin inhibitors | |
|---|---|
| Anti-inflammatory products for vaginal administration | |
| Estrogens |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antiestrogens |
| ||||||||
| |||||||||
| Progestogens (and progestins) |
| ||||
|---|---|---|---|---|---|
| Antiprogestogens |
| ||||
| |||||
| GnRH modulators (incl. analogues) |
| ||||
|---|---|---|---|---|---|
| Gonadotropins |
| ||||
| Others (indirect) |
| ||||
| |||||
Urologicals, including antispasmodics (G04B) | |
|---|---|
| Acidifiers | |
| Urinary antispasmodics (primarily antimuscarinics) | |
| Other urologicals | |
| Erectile dysfunction |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Premature ejaculation |
| ||||||||||||